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Abstract
Background: Glucagon-like peptide-1 (GLP-1) is recognized as an important regulator of glucose homeostasis. Efforts to
utilize GLP-1 mimetics in the treatment of diabetes have yielded clinical benefits. A major hurdle for an effective oral therapy
has been the difficulty of finding a non-peptidic GLP-1 receptor (GLP-1R) agonist. While its oral bioavailability still poses
significant challenges, Boc5, one of the first such compounds, has demonstrated the attainment of GLP-1R agonism in
diabetic mice. The present work was to investigate whether subchronic Boc5 treatment can restore glycemic control and
induce sustainable weight loss in diet-induced obese (DIO) mice, an animal model of human obesity and insulin resistance.
Methodology/Principal Findings: DIO mice were treated three times a week with Boc5 (0.3, 1 and 3 mg) for 12 weeks. Body
weight, body mass index (BMI), food intake, fasting glucose, intraperitoneal glucose tolerance and insulin induced glucose
clearance were monitored regularly throughout the treatment. Glucose-stimulated insulin secretion, b-cell mass, islet size,
body composition, serum metabolic profiles, lipogenesis, lipolysis, adipose hypertrophy and lipid deposition in the liver and
muscle were also measured after 12 weeks of dosing. Boc5 dose-dependently reduced body weight, BMI and food intake in
DIO mice. These changes were associated with significant decreases in fat mass, adipocyte hypertrophy and peripheral
tissue lipid accumulation. Boc5 treatment also restored glycemic control through marked improvement of insulin sensitivity
and normalization of b-cell mass. Administration of Boc5 (3 mg) reduced basal but enhanced insulin-mediated glucose
incorporation and noradrenaline-stimulated lipolysis in isolated adipocytes from obese mice. Furthermore, circulating leptin,
adiponectin, triglyceride, total cholesterol, nonesterified fatty acid and high-density lipoprotein/low-density lipoprotein
ratio were normalized to various extents by Boc5 treatment.
Conclusions/Significance: Boc5 may produce metabolic benefits via multiple synergistic mechanisms and may represent an
attractive tool for therapeutic intervention of obesity and diabetes, by means of non-peptidic GLP-1R agonism.
Citation: He M, Su H, Gao W, Johansson SM, Liu Q, et al. (2010) Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor
Agonist in Diet-Induced Obese Mice. PLoS ONE 5(12): e14205. doi:10.1371/journal.pone.0014205
Editor: Kathrin Maedler, University of Bremen, Germany
Received July 10, 2010; Accepted November 11, 2010; Published December 3, 2010
Copyright:  2010 He et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by grants from the Ministry of Science and Technology of China (2009ZX09302-001), the Chinese Academy of Sciences
(KSCX1-YW-02-2 and KSCX2-YW-R-17), the Natural Science Foundation of China (30628024 and 30623008), Shanghai Science and Technology Development Fund
(08DZ2291300, 09DZ2291200 and 074319114) and the CAS-Novo Nordisk Research Fund. The funding agencies had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JL is a co-founder and consultant to Argus Biosciences LLC.
* E-mail: wangmw@mail.shcnc.ac.cn
¤a Current address: Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, United States of America
¤b Current address: Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
¤c Current address: Department of Bioengineering, University of California Riverside, Riverside, California, United States of America
¤d Current address: Enteroendocrine Biology, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
Introduction
In the past decades, obesity has become a worldwide epidemic
due to excessive energy intake and lack of physical exercises [1,2].
Associated with obesity, metabolic disorders including hyperinsu-
linemia, impaired glucose tolerance and dyslipidemia are often
observed, which increase the risk for type 2 diabetes mellitus
(T2DM), cancer and heart diseases [3–7]. Although diet control
and life style modification remain the first steps in obesity
management [8,9], the use of pharmaceutical agents may
sometimes be indispensable for long-term treatment of obesity
[10].
Gastrointestinal hormones secreted in response to nutrient
ingestion play essential roles at multiple levels in the regulation of
energy homeostasis [11], and have been regarded as potential
therapeutic targets for safe and sustainable weight loss [12].
Glucagon-like peptide-1 (GLP-1), an insulinotropic gastrointestinal
peptide produced mainly from intestinal endocrine L-cells, inhibits
glucagon secretion, stimulates glucose-dependent insulin produc-
tion, improves insulin sensitivity, delays gastric emptying as well as
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agonists, exemplified by the first incretin mimetic, Exendin-4
(Exenatide), exert many of the glucose regulatory actions observed
with GLP-1 [17], thereby possessing favorable effects in the
treatment of T2DM [18]. In addition to the benefits in glycemic
control, chronic treatment of GLP-1 analogues was also capable of
inducing significant weight loss in rodents or patients with T2DM
[18,19]. Hence, GLP-1R agonists represent a promising class of
new drugs with dual anti-obesity and anti-diabetic properties [20].
The approach to elevate endogenous GLP-1 levels by inhibition
of the predominant GLP-1 degrading enzyme, dipeptidyl
peptidase-IV (DPP-IV), has been proven useful for T2DM
treatment [21], but does not seem to fully capture the anti-
diabetic potential of GLP-1R agonism [22] in terms of promoting
weight loss [23]. All the GLP-1R agonists developed to date, or
currently under development, are of peptidic nature and this
imposes certain limitations on their administration. Thus, there is
considerable interest in the development of non-peptidic GLP-1R
agonists [24,25].
We have previously identified a substituted cyclobutane, Boc5,
that acts in vitro and in vivo as a full GLP-1R agonist [26]. Boc5 is a
small molecule compound with reasonable affinity for GLP-1R
and good safety profile in vivo. It could simultaneously activate a
broad spectrum of anti-diabetic effects including decline of blood
glucose, inhibition of food intake, slowing of gastric emptying,
stimulation of insulin secretion, elevation of insulin sensitivity and
reduction of body weight in diabetic db/db mice [27]. Nevertheless,
the db/db mice, as a leptin receptor-deficient rodent model, are
unable to fully represent the pathogenesis of human obesity/
diabetes. Many studies have used high fat diet (HFD) fed rodents
to recapitulate the polygenic features of obesity that mimic human
consumption patterns. This diet-induced obesity (DIO) model has
been shown to be most efficient in C57BL/6J (C57) mice
compared with other strains [28,29]. When fed HFD, C57 mice
are characteristic of overweight, hyperglycemia, hyperinsulinemia,
glucose intolerance as well as dyslipidemia [30]. In the present
study, we investigated a variety of metabolic consequences
following subchronic Boc5 treatment of DIO mice to explore
the potential therapeutic utility of this new class of GLP-1
mimetics.
Results
Effect on body weight
Before initiation of Boc5 treatment, C57 mice were fed HFD for
12 weeks and only those that reached a body weight of $40 g and
body mass index (BMI) of $0.39 g/cm
2 [45.5% and 30.0% more
than that of standard chow diet (SCD) controls, respectively] were
selected and randomly distributed to each study group (Figures 1A
and 1B). Intermittent Boc5 administration (3 times per week, tiw)
led to a dose-dependent and significant reduction in body weight
and BMI, which sustained over the entire treatment period (12
weeks). The mice ultimately exhibited 8.0 g (1 mg dose) to 13.3 g
(3 mg dose) weight loss, or approximately 17.6% to 29.2%
reduction from the level seen in vehicle-treated obese controls
(45.6 g in weight); this was accompanied by a consistent and
parallel decrease in BMI measurements (P,0.0001; Figures 1A
and 1B). The corresponding ED50 values estimated were 0.9 mg
for weight loss and 0.7 mg for BMI decrease, respectively
(Figure 1C). For pair-fed mice constrained to a food intake
equivalent to that of the 3 mg Boc5 treatment group, although a
similar weight and BMI changes were observed, the effect was less
pronounced than the Boc5-treated counterparts (P,0.01;
Figures 1A and 1B). While Boc5 dose-dependently (P,0.0001)
induced weight loss and BMI reduction in DIO mice, only the
3 mg dose produced a weight loss indistinguishable from SCD
controls (P=0.0684 for body weight and P=0.0765 for BMI;
Figures 1A and 1B). Similar to our previous findings in db/db mice,
Boc5 dose-dependently inhibited cumulative food intake by up to
17% (approximately 11.5% of daily food intake) throughout the
12-week treatment course, and Boc5-treated mice (3 mg) ingested
nearly the same amount of food as mice fed SCD (Figure 1D).
Effects of subchronic Boc5 treatment on body composition were
examined in follow-up experiments. The brown fat and four white
fat (mesenteric, inguinal, retroperitoneal and gonadal) depots
sampled were about 1.2- to 3.4-fold heavier as a percentage of
body weight in HFD mice than that of SCD controls prior to the
treatment (Figure S1). When normalized for body weight after 12-
week Boc5 injection, the weights of white fat pads, as well as
brown fat pad (1 and 3 mg groups), were significantly reduced
(P,0.0001, P=0.0164 and P=0.0022, respectively) (Figure 1E).
Total fat analysis indicated that Boc5 treatment proportionately
brought the body composition profile of obese mice close to that of
lean animals (3 mg Boc5 group became indistinguishable,
P=0.41). The 10.3 g loss of total fat mass following 3 mg Boc5
treatment, calculated from the percentage of body weight,
accounted for 77% of the 13.3 g weight reduction, relative to
obese controls (Figure 1E). Notably, although pair-fed mice
revealed obvious downward trend of total fat mass, the effect
failed to reach the same level of the 3 mg Boc5 dose group.
The serum levels of leptin and adiponectin, two important
adipocytokines secreted from white adipose tissue (WAT), were
also altered after Boc5 treatment. Circulating leptin concentration
in DIO mice was significantly higher than that in SCD controls
(19.7 ng/ml vs. 1.5 ng/ml, P,0.0001). In contrast, Boc5 (3 mg)
administration significantly (P,0.0001) reduced serum leptin level
to a near normal value of 2.3 ng/ml (Figure 1F). Figure 1G shows
that, prolonged exposure to HFD induced a 38% lower serum
adiponectin level in DIO than in lean mice (P=0.0004), whereas
this level was remarkably increased (P,0.0001) by Boc5 to the
normal range observed in SCD fed controls (11.7 mg/ml in 3 mg
group vs. 11.9 mg/ml in SCD group). Although pair-fed mice
displayed certain degree of improved circulating leptin and
adiponectin concentrations, the effects were relatively marginal
and not as pronounced as seen in 3 mg Boc5-treated animals
(P=0.0003 for leptin and P=0.0444 for adiponectin; Figures 1F
and 1G).
Effect on adipocyte morphology
Histological analysis revealed that mice on HFD had larger
white (inguinal) adipocytes and an increased accumulation of lipids
in brown adipocytes relative to SCD controls; Boc5 treatment led
to a substantial decrease in the size of adipocytes in inguinal WAT
(Figure 2A); similar results were also observed in brown adipose
tissue (BAT). Brown fat in vehicle-treated obese mice resembled
white fat with a few massive lipid droplets invading in each brown
adipocyte, while Boc5 treatment reversed such lipid deposition via
replacing large lipid droplets with multiple small ones (Figure 2B).
Morphometric analysis of adipocyte distribution along with their
sizes indicated that Boc5 increased the population of small-sized
adipocytes and decreased the population of large-sized adipocytes
in WAT. As shown in Figure 2C, the size of white adipocytes in
the 3 mg Boc5-treated group (466621 mm
2) was dramatically
smaller than that in vehicle-treated controls (38846249 mm
2) and
reached the adjacent level of SCD fed lean mice (292615 mm
2). In
contrast, although the fat cell size in pair-fed mice became smaller
and was equivalent to about 50% (1964680 mm
2) of obese mice, it
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(Figures 2A and 2C).
Effects on glucose uptake and lipolysis
To investigate whether lipid metabolism was modified after
subchronic Boc5 therapy, ex vivo experiments were carried out
using the adipocytes isolated from treated mice. We first examined
the glucose uptake capacity of gonadal adipocytes from four
different treatment groups (SCD, HFD, 3 mg of Boc5 and pair-
fed) by measuring the incorporation of D-[3-
3H]glucose into lipids,
as an index of lipogenesis. As shown in Figure 3A, the value of
basal glucose incorporation was significantly increased in obese
mice compared with that in lean controls (P=0.0213). Boc5
treatment, but not pair-feeding, was able to reduced this high basal
glucose uptake (P=0.0082) towards the normal level (P=0.3289).
It follows that the action of insulin to stimulate glucose
Figure 1. Effects of Boc5 on body weight, BMI, food intake, adiposity and circulating adipocytokine concentrations. (A) Time course
of the effect on body weight (n=16 per group). (B) BMI monitored before, during and after the treatment (n=6 per group). (C) Dose-response
profiles for weight (D-body weight) and BMI (D-BMI) changes over the 12-week period (n=16 per group for weight and n=6 per group for BMI). (D)
Time course of the effect on cumulative and daily food intake (insert) (n=16 per group). (E) Dose-dependent effects on whole fat mass (n=6 per
group), white and brown adipose tissues (WAT and BAT) as percentage of body weight (n=8–14 per group). WAT were represented by mesenteric,
inguinal, retroperitoneal and gonadal fat pads. (F) Serum leptin and (G) adiponectin levels measured at the end of the treatment (n=9 for SCD and
HFD groups; n=6 for Boc5-treated groups). (H) Effects on the gross appearance of body shape (upper panel), abdominal fat (middle panel) and fat
depots (lower panel) recorded at autopsy. Values represent mean6SEM.
DP,0.05 and
DDP,0.01 compared with SCD group;
*P,0.05 and
**P,0.01
compared with HFD group;
#P,0.05 and
##P,0.01 compared with pair-fed group that received an equal amount of food as 3 mg Boc5-treated
mice.
doi:10.1371/journal.pone.0014205.g001
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(Figure 3B), that was partially reversed by Boc5 treatment
(increased by 1.8-fold compared to obese controls), with an
estimated EC50 value for insulin of 67.3 mIU/ml (315.0 mIU/ml in
untreated animals), thereby pointing to a significant improvement
of insulin sensitivity. Although insulin-dependent glucose incorpo-
ration was also partially restored in pair-fed controls (Figure 3B),
the effect was much less pronounced than in their Boc5-treated
counterparts.
We also assayed the levels of basal and L-noradrenaline (NA)-
stimulated glycerol released to the culture medium from isolated
adipocytes as an indicator of triglyceride metabolism. As shown in
Figure 3C, basal lipolysis in DIO mice was significantly higher
than that in lean animals (0.28 mM and 0.12 mM, respectively,
P,0.0001), whereas Boc5, rather than the pair-fed control, led to
a 46.4% decrease in basal glycerol release, albeit not completely
normalized (P,0.0001). The concentrations of NA (3, 30 and
300 nM) used in this study were chosen according to the literature
[31], which indeed caused dose-dependent increases (ED50=
11.3 nM) of lipolysis in SCD fed mice (Figure 3D). In the obese
group, however, NA-stimulated lipolytic activity was significantly
suppressed (ED50=26.5 nM); Boc5 treatment resulted in an
evident improvement (ED50=13.2 nM), while lipolytic response
to NA in pair-fed mice was only minimally recovered
(ED50=18.6 nM; Figure 3D).
Effects on glycemic control and insulin sensitivity
High fat feeding induced mild hyperglycemia in obese mice
compared to those received a regular chow diet, with basal fasting
glucose levels ranging from 4.460.4 mM (lean) to 8.062.1 mM
(obese) (P=0.0012; Table 1). The latter value was progressively
worsened to around 12 mM over the 12-week observation period
in DIO mice treated with vehicle or low doses of Boc5 (0.3 and
1 mg). In contrast, the 3 mg dose led to a significant decrease in
fasting glucose (8.360.9 mM, P,0.0001) to the comparable level
seen in lean animals (7.161.5 mM, P=0.1260). Nevertheless, the
effect of pair-feeding was only marginal (11.361.9 mM,
P=0.5771 vs. obese mice; Table 1).
Glucose tolerance was quantified as the area-under-curve
integrated from 0–120 min (AUC120) after an intraperitoneal
glucose tolerance test (IPGTT). Prior to initiating therapy with
Boc5, DIO mice showed impaired glucose tolerance relative to
SCD controls (P,0.0001; Figure 4A, Figure S2), it was
progressively improved during the course of Boc5 treatment
Figure 2. Effects of Boc5 on adipocyte morphology. Histological analysis of inguinal white (A) and brown (B) adipocytes isolated from lean
(SCD) and obese (HFD) mice that received vehicle, Boc5 (3 mg) or pair-fed treatment (n=3 per group). Sections (5 mm) were stained with H&E and
representative images (6200 original magnification) obtained at the end of the 12-week observation period. (C) Distribution of the white adipocyte
cell size. The mean surface area and the frequency distribution were calculated based on at least 500 cells from each mouse. Scale bars=50 mm.
doi:10.1371/journal.pone.0014205.g002
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therapy revealed a dose-dependent restoration (P,0.0001) of
glucose tolerance, such that the glucose profile of mice receiving 1
and 3 mg Boc5 was indistinguishable from that of SCD fed mice
(P=0.0626 and P=0.3899, respectively; Figure 4A). Thus, the
normalization of the glucose profile appeared to reflect a
combination of reduction in fasting glucose, modification of
glucose excursion and an altered rate of decay of circulating
glucose (see below). Serum levels of glucose-stimulated insulin were
simultaneously monitored in the same experiment. DIO mice
Figure 3. Effects of Boc5 on glucose uptake and lipolysis in isolated adipocytes. (A) Basal glucose uptake in the absence of insulin after 2 h
of incubation. Data shown are the relative quantities of intracellular [3-
3H]glucose normalized by the total lipid content. (B) Insulin-stimulated glucose
incorporation expressed as a percentage of the basal response. (C) Basal lipolysis in the absence of noradrenaline after 1 h of incubation. Data shown
are the absolute concentrations of glycerol resulted from triglyceride hydrolysis. (D) Noradrenaline-stimulated glycerol release expressed as a
percentage of the basal response. Values represent mean6SEM of two to five independent ex vivo studies using adipocytes isolated from two
(glucose uptake) or four (lipolysis) mice for each experiment.
DP,0.05 and
DDP,0.01 compared with SCD group;
**P,0.01 compared with HFD group;
##P,0.01 compared with pair-fed group that received an equal amount of food as 3 mg Boc5-treated mice.
doi:10.1371/journal.pone.0014205.g003
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increased more than 7-fold compared to SCD controls
(P=0.0003). In contrast, subchronic administration of 3 mg
Boc5 induced a dose-dependent (P=0.0007) reduction of overall
insulin excursion by up to 85% (P=0.0062) after an intraperito-
neal (i.p.) glucose challenge (Figure 4B). This was accompanied by
a significant and dose-dependent (P=0.0225) diminishment of
pancreatic insulin content in DIO mice following 12 weeks of Boc5
treatment, a phenomenon that was not observed in pair-fed
controls (Figure 4C). Further, despite equal energy consumption
and submaximal weight loss, unlike 3 mg Boc5-treated DIO
counterparts, pair-fed mice still exhibited deterioration of glucose
tolerance (P,0.0001; Figure 4A) and hyperinsulinemia
(P,0.0001; Figure 4B) during this period.
The data of Boc5 treatment on glucose homeostasis and
hyperinsulinemia were suggestive of improvement in insulin
sensitivity. To verify this, a separate set of insulin tolerance tests
(ITT) experiments were carried out to measure the rate of glucose
clearance in response to exogenous insulin. The overall glucose
response in mice is typically consisting of an initial fall (attributable
to insulin) followed by a rise (attributable to glucagon and other
counter-regulatory hormones) in serum concentrations. As expect-
ed, the initial rate of glucose fall in response to 2 IU/kg
recombinant human insulin (Kitt) was 1.9-fold higher in lean than
in obese mice (P=0.0138); it was increased in a dose-dependent
manner up to 1.8-fold in DIO mice receiving subchronic Boc5
(3 mg) administration (P=0.0190). Pair-fed mice, however,
showed a restoration trend but failed to reach the similar level
seen in the 3 mg Boc5-treated group (Figure 4D).
Effect on the pancreas
After 12 weeks of treatment, total pancreatic weight did not
differ among lean, obese, Boc5-treated and pair-fed groups (data
not shown). Histological examination revealed the frequent
appearance of larger islets and microvesicles in islet cells of obese
mice. Enlarged interlobular interspaces and lipid deposition were
also found in some pancreatic specimens, but inflammatory cell
infiltration was not obvious and only a few lymphocytes were
observed in inter- or intra-lobular areas. Such alterations were
greatly diminished following Boc5 treatment whereas the histo-
logical changes seen in pair-fed mouse pancreases remained
notably significant (Figure S3).
Absolute b-cell mass was decreased by 59% in the 3 mg Boc5-
treated group (1.1760.27 mg/pancreas, P=0.000146) and 31%
in the pair-fed group (1.9760.47 mg/pancreas, P=0.005878),
respectively, compared to the obese group (2.8660.64 mg/
pancreas). The difference between Boc5 (3 mg) treated obese
and lean mice was negligible (P=0.8842; Figure 5A). The changes
in b-cell mass were consistent with both fasting serum insulin levels
and pancreatic insulin contents measured simultaneously
(Figures 4B and 4C).
WealsoexaminedalterationsinisletsizefollowingBoc5treatment.
Islets weredivided into three categories: small(,1000 mm
2),medium
(1000–20000 mm
2)a n dl a r g e( .20000 mm
2). It was found that obese
mice receiving Boc5 had a decreased islet size compared to that of
untreated ones (35116350.8 mm
2 vs. 106306806.0 mm
2, P,0.0001;
Figure 5B). This was accompanied by a marked increase in small
islets in Boc5-treated mice as opposed to obese controls: the
percentage of large islets was 3.33% vs.1 9 . 0 2 %( P=0.0002) while
that of small islets was 42.72% vs. 20.85%, respectively (P=0.0035;
Figure 5C). It appears that the reduction of b-cell mass induced by
Boc5 might be resulted from such a dramatic rise in the number of
small islets (Figure S4).
Effects on liver/muscle weight, triglyceride content and
liver morphology
Compared with SCD, HFD feeding for 12 weeks significantly
increased net liver weight by approximately 29.2% (P=0.0002;
Figure 6A). Boc5 treatment led to a dose-dependent decrease in
liver weights by 9.6%, 15.6% and 18.3% for 0.3 mg, 1 mg and
3 mg doses, respectively, among which the reduction induced by
3 mg of Boc5 was statistically significant (P=0.0213, compared to
untreated obese mice). Surprisingly, similar reduction (about
23.4%, P=0.01797) was also observed in pair-fed animals, though
their total adipose tissue weight was heavier than that of Boc5
(3 mg) treated group. There seemed to be a tendency of increased
gastrocnemius muscle weight (+27.6%) in obese mice but the
difference was not statistically meaningful in comparison with
lean controls (P=0.0639). Boc5 administration, other than pair-
feeding, displayed a significant reduction of liver weight
(P=0.0473; Figure 6A).
Histological examination also confirmed these findings. Liver
sections from DIO mice exhibited extensive intracellular vacuolization
and significant lipid accumulation in both perivenular and periportal
areas (Figure 6D). In contrast, only scattered small lipid droplets were
detected in the liver from Boc5 (3 mg) treated animals (Figure 6E).
For further analysis, liver and muscle lipids were extracted for
determination of triglyceride (TG) levels (Figure 6B). Compared
Table 1. Fasting blood glucose levels (mM) measured before and during Boc5 treatment.
HFD
Weeks SCD Vehicle Boc5 0.3 mg Boc5 1 mg Boc5 3 mg Pair-fed
0 4.460.4 8.062.1
DD 8.062.1 8.062.1 8.062.1 8.062.1
3 5.861.0 9.061.9
DD 8.261.3 9.762.1 7.561.0
# 9.260.8
6 5.760.6 9.561.5
DD 8.261.3 10.660.4 8.061.2
*, # 11.262.2
9 6.461.0 11.060.7
DD 11.361.4 11.262.2 9.560.6
**, # 11.461.7
12 7.161.5 12.162.4
DD 12.060.9 11.961.3 8.360.9
**, ## 11.361.9
Values represent mean6SEM (n=6–10 per group).
DDP,0.01 vs. normal diet (SCD) group;
*P,0.05 and
**P,0.01 vs. high fat diet (HFD) group that received vehicle treatment;
#P,0.05 and
##P,0.01 vs. HFD group that was pair-fed an equal amount of food as 3 mg Boc5-treated mice.
doi:10.1371/journal.pone.0014205.t001
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32.8% (P=0.0278) and 139.5% (P,0.0001) in DIO mice,
respectively. Boc5 dose-dependently reduced TG contents in these
tissues by up to 23.3% (liver) and 35.0% (muscle), respectively,
throughout the 12 weeks of treatment. The concentration of TG in
the liver, rather than in the muscle, was significantly decreased in
pair-fed mice in comparison with obese controls (P=0.0044).
Effect on blood chemistry
Recent evidence suggests that obesity and insulin resistance
represent important risk factors for steatohepatitis [32]. In the present
study, hepatocyte damage was assessed by examining serum enzyme
activities of alanine aminotransferase (ALT) and aspartate amino-
transferase (AST). Our data (Table 2) showed that ALT concentration
was 2.5-fold higher in obese than in lean mice (P=0.0008). Boc5
treatment resulted in a reduction at each dose studied (0.3, 1 and
3 mg), though there was no apparent dose-response relationship
observed (47.9–57.1% decreases). Pair-feeding was also able to reduce
ALT level by 45.2%, similar to the effect of 3 mg Boc5 (P.0.05).
Serum AST concentration in DIO mice was trending higher than in
SCD controls (P=0.071), but only at the 3 mg dose, Boc5 evoked a
significant decrease (P=0.0003) in AST level.
Serum TG, total cholesterol (TC) and nonesterified fatty acid
(NEFA) levels were markedly elevated in obese mice (P=0.0049,
Figure 4. Effects of Boc5 on glucose homeostasis and insulin sensitivity. (A) Intraperitoneal glucose tolerance test (IPGTT) after 12 weeks of
Boc5 treatment in diet-induced obese (DIO) mice (n=6–8 per group). The pink and gray bands respectively denote mean6SD of blood glucose levels
measured in obese (HFD) and lean (SCD) mice prior to treatment. The glucose area-under-curve integrated from 0–120 min (AUC120) was calculated
for each mouse. (B) Serum insulin response to an intraperitoneal glucose challenge one day after the cessation of Boc5 therapy. The insulin area-
under-curve integrated from 0–60 min (AUC60) was calculated for each mouse (n=8 per group). (C) Pancreatic insulin content measured at the end of
treatment (n=6–9 per group). (D) Effect on Kitt, a measure of insulin-mediated glucose clearance, in each treatment group (n=8 per group). Values
represent mean6SEM.
DP,0.05 and
DDP,0.01 compared with SCD group;
*P,0.05 and
**P,0.01 compared with HFD group;
#P,0.05 compared
with pair-fed group that received an equal amount of food as 3 mg Boc5-treated mice.
doi:10.1371/journal.pone.0014205.g004
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software and calculated by multiplying the percentage of insulin-immunostained area by pancreatic weight. (B) The area of each islet was assessed by
manually drawing around the islet perimeter with the measuring tool contained in the software. The total numbers of islets counted for each group
were: 262, 299, 280 and 263, respectively. Y-Axis represents the islet size that was divided into three fractions: small, medium and large. (C)
Distribution of small, medium and large islets as a percentage of the total islets in obese mice with or without 3 mg Boc5 treatment. Values represent
mean6SEM.
DDP,0.01 compared with SCD group;
*P,0.05 and
**P,0.01 compared with HFD group;
##P,0.01 compared with pair-fed group that
received an equal amount of food as 3 mg Boc5-treated mice.
doi:10.1371/journal.pone.0014205.g005
Figure 6. Effects of Boc5 on liver/muscle weight (A), triglyceride (TG) content (B) and liver morphology (C–F). The weights of liver and
muscle from each treatment group and SCD control were determined after 12 weeks of treatment and the TG content examined following tissue lipid
extraction. Values represent mean6SEM (n=6–8 per group).
DP,0.05 and
DDP,0.01 compared with SCD group;
*P,0.05 and
**P,0.01 compared
with HFD group;
#P,0.05 compared with pair-fed group that received an equal amount of food as 3 mg Boc5-treated mice. Histological analysis was
performed on the liver tissue from lean (C), obese (D), 3 mg Boc5 (E) and pair-fed (F) treated mice, respectively (n=3 per group). Sections (5 mm) were
stained with H&E and representative images (6200 original magnification) obtained after the 12-week observation period. Scale bars=50 mm.
doi:10.1371/journal.pone.0014205.g006
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Boc5 (3 mg) treatment, but not pair-feeding, reversed these
metabolic parameters (P,0.0001, P,0.0001 and P=0.0387,
respectively, compared to obese mice), which became indistin-
guishable from that seen in SCD fed animals. In addition,
measurement of circulating high-density lipoprotein (HDL) and
low-density lipoprotein (LDL) elicited an unexpected but explain-
able [33,34] result that both ‘‘good’’ (HDL) and ‘‘bad’’ (LDL)
cholesterol values were increased after HFD feeding (data not
shown). We therefore calculated the LDL/HDL ratio to analyze
the magnitude of increases in the two lipoproteins among different
treatment groups. As shown in Table 2, long-term exposure to
HFD increased the LDL/HDL ratio by 45%, which was reduced
to the normal range following Boc5 administration (1 and 3 mg) or
diet suppression (P=0.0019, P=0.0036 and P=0.0038, respec-
tively).
Discussion
GLP-1 is recognized as an important endogenous regulator of
glucose and lipid homeostasis. Efforts to utilize GLP-1 analogs or
GLP-1R agonists in the treatment of T2DM and obesity have
lasted for decades. The successful clinical use of Exendin-4 and
Liraglutide [19] - injectable peptidic GLP-1R agonists and
multiple ongoing human trials with other GLP-1 peptidomimetics
all support the idea that GLP-1 analogs are probably the most
beneficial therapeutic agents for T2DM in today’s medical
practices [20]. The major pharmaceutical hurdle for an effective
oral treatment has been the difficulty to find a non-peptidic GLP-
1R agonist with a long half-life [35]. Boc5 is one of the first such
compounds that demonstrated an array of therapeutic actions in
the treatment of diabetes and obesity in db/db mice [26,27]. Boc5
efficiently induced a durable restoration of glycemic control and its
other dose-dependent effects include reduction in food intake,
slowing of gastric emptying, stimulation of insulin secretion and
elevation in insulin sensitivity following 4 weeks of daily
administration. It also decreased body weight of diabetic db/db
mice but required a high dose (3 mg per day) [27]. In the present
study, we employed a rodent model of DIO to overcome the
shortcomings of previously used genetic model (the db/db mouse)
and thus to provide data with more relevance to human diseases:
obesity and T2DM [30]. DIO model can in part mimic human
energy consumption patterns and gives the possibility of studying
the pathogenesis of obesity and related diseases (e.g., T2DM) and
examining the consequences of therapeutic intervention [36,37].
This model was originally introduced by Surwit et al. in 1988 [38]
and has been shown to be most efficient in C57 mice compared
with other strains [28,29]. Therefore, this was the rationale of
utilizing HFD fed C57 mice to advance our understanding on the
pharmacological properties of Boc5 in diet-induced obesity and
related metabolic disorders.
During the 12-week induction period with HFD, energy
consumption of C57 mice was significantly increased and their
body weight gained progressively, leading to moderate hypergly-
cemia, glucose intolerance and hyperinsulinemia. A pilot exper-
iment was performed to determine the treatment regimen with
Boc5, in which drastic weight loss was observed following daily
dosing especially at 3 mg (data not shown). In order to avoid
possible adverse consequences [39,40], we applied an intermittent
(tiw) dosing schedule to the present work. Our results clearly
demonstrate that subchronic Boc5 treatment invoked marked
suppression of food intake and sustained reduction of body weight
in DIO mice with both 1 mg and 3 mg doses (Figures 1A, 1C and
1D). Although similar effects were seen in db/db mice, Boc5 at a
daily dose of 1 mg failed to induce marked weight loss [27]. The
anti-obesity action of Boc5 is in agreement with a recent study
with Exendin-4 conducted in HFD fed C57 mice [41]. While the
weight-lowering effect of Exendin-4 mainly occurred in the first
week of treatment [41], Boc5 seemed to manifest its regulatory
role in a more sustainable manner, i.e., affecting the entire therapy
period. As a result, a 30% loss from the initial body weight was
achieved (Figure 1A) and maintained for at least 7 weeks after the
cessation of Boc5 therapy (3 mg; Figure S5). This long-lasting
benefit is consistent with that observed in rats following
administration of GLP-1 [42]. Such a ‘‘memory effect’’ is probably
attributable to its action on the transcription of key regulator genes
controlling b-cell mass and function [41,42]. BMI, an index
reflecting severity of obesity derived from body weight and body
length [43], was dose-dependently suppressed by Boc5 treatment,
suggesting an ameliorated obese state in DIO mice (Figures 1B
and 1C). Interestingly, despite equal energy intake, the pair-fed
group showed body weight reductions only in the beginning of the
12-week treatment period and the effect was less pronounced than
the Boc5-treated (3 mg, tiw) group. We presume that this
phenomenon may have been caused by reduced body temperature
Table 2. Effects of Boc5 on serum biomarkers examined at the end of the 12-week therapy.
HFD
SCD Vehicle Boc5 0.3 mg Boc5 1 mg Boc5 3 mg Pair-fed
ALT (IU/L) 22.71610.78 56.58625.84
DD 29.50615.05
** 24.2567.07
** 28.2965.32
** 31.3864.24
**
AST (IU/L) 131.79626.46 150.33621.27 159.38633.95 131.63632.72 111.88615.6
**, # 136.25620.24
TC (mM) 2.5960.75 5.2060.97
DD 4.4060.44
* 3.4360.56
** 2.5460.20
**, ## 5.1460.35
TG (mM) 1.0260.37 1.4460.32
DD 1.4660.18 1.2160.21 0.7060.20
**, ## 1.4560.26
NEFA (mM) 1.1160.22 1.4360.22
DD 1.3860.17 1.2660.19 1.1660.29
*, ## 1.5560.35
LDL/HDL 0.2460.16 0.3460.08
D 0.3160.06 0.2360.06
** 0.2560.04
**, # 0.2460.06
**
Values represent mean6SEM (n=8–12 per group).
DP,0.05 and
DDP,0.01 vs. normal diet (SCD) group;
*P,0.05 and
**P,0.01 vs. high fat diet (HFD) group that received vehicle treatment;
#P,0.05 and
##P,0.01 vs. HFD group that was pair-fed an equal amount of food as 3 mg Boc5-treated mice.
doi:10.1371/journal.pone.0014205.t002
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compensatory mechanism to conserve energy [44,45].
For an ideal anti-obesity therapy, it is preferable that the weight
loss stems predominantly from fat. In the present study, the
remarkable decrease in body weight was accompanied by a dose-
dependent reduction in fat as a percentage of body weight
(Figure 1E). Analysis of carcasses from Boc5-treated DIO mice
indicates that the body mass was preferentially lost from fat. On
the other hand, despite the observed fat diminishment, such
regulated loss invoked by Boc5 did not reach the extent to bring
adverse consequences that often occurs in adipose tissue ablated
mice [39,40]. It is known that increase in adipocyte size due to fat
storage (adipocyte hypertrophy) plays a key role in the formation
of adipose tissue mass, and such conversion from small into large
adipocytes is closely related to common health risks including
hyperlipidemia, diabetes, hypertension and cardiovascular diseases
[46]. Our histological examination suggests that increases of fat
deposits in adipose tissue were accompanied by white and brown
adipocyte hypertrophy in HFD fed obese mice (Figures 2A and
2B). In contrast, white adipocytes from Boc5-treated mice
appeared to be smaller in size than that from vehicle-treated
controls, an observation consistent with the low TG and NEFA
levels in the circulation (Figures 2A and 2C, Table 2). Boc5
treatment also led to a reduction of lipid content in brown
adipocytes (Figure 2B) thereby reflecting the adaptive status of
BAT in regulating thermogenesis [47,48].
Adipose tissue has a substantial influence on systemic metabolic
homeostasis via its role as an endocrine organ capable of secreting
diverse adipocytokines [49,50]. The dose-dependent reduction of
serum leptin level towards the normal range observed in Boc5-
treated mice (Figure 1F) supports the existence of a correlation
between circulating leptin and adiposity. This phenomenon was
accompanied by simultaneous restoration of circulating adipo-
nectin concentration to a level that is completely normal
(Figure 1G). Such an altered secretion associated with changes
in adiposity is suggestive of a potential role for adiponectin as an
autocrine factor in WAT to modulate adipocyte size (secretion
increases when fat mass is reduced but it decreases following fat
deposition) [51]. Different from Boc5 treatment, caloric restriction
did not affect adiposity significantly and circulating adipocytokines
levels remained abnormal (Figures 1E–1G and Figure 2). These
apparent differences imply that the regulatory role exerted by
Boc5 (and hence, incretin mimetics in general) on lipid metabolism
is independent of its inhibition on food intake.
Numerous studies have suggested that obesity is accompanied
by several related metabolic defects in adipocytes concerning
glucose or free fatty acid uptake, lipolytic activity and lipid
oxidation [52]. Our results indicate that the basal glucose
incorporation was significantly elevated in adipocytes isolated
from obese mice while their response to insulin stimulation was
severely impaired (Figures 3A and 3B). Although there are
conflicting reports regarding the alteration in the basal glucose
uptake, most previous findings demonstrate that insulin-induced
glucose incorporation is suppressed in the obese state [53–55].
Meanwhile, we observed that the basal lipolytic activity was
increased in obese mouse adipocytes that also displayed evident
resistance to NA stimulation (Figures 3C and 3D). This finding is
consistent with earlier results obtained from human or animal
adipocytes [56,57]. There is evidence suggesting that increased
cAMP and tumor necrosis factor a (TNF-a) production in fat cells
from obese individuals may be responsible for the enhancement of
basal lipolysis [58,59], whereas lipolytic resistance is probably due
to decreased expression of b2-adrenoceptors [57] and hormone-
sensitive lipase (HSL) capable of hydrolyzing TG [60]. Even if
Boc5 treatment did not normalize basal and stimulated glucose
uptake and lipolysis in our ex vivo experiments, the improvements
were impressive (Figure 3), especially in the context that both
GLP-1 and Exendin-4 only exhibited modest effects on fat cell (rat
or human) metabolism when introduced directly to culture
medium [55,61–64]. Similar to the data described elsewhere
[54], the role of caloric restriction (pair-feeding) in modifying fat
cell lipogenesis and lipolysis was minimal (Figure 3), thereby
further supporting the existence of an anorexia-independent
pathway for Boc5 in modulating lipid metabolism.
It is well established in C57 mice that consumption of HFD
results in both moderate hyperglycemia and progressive hyperin-
sulinemia, leading to eventual insulin resistance [30]. In the
present study, we observed that fasting glucose levels in untreated
obese mice were deteriorating with time while Boc5 could reverse
such a tendency (Table 1). Combined with the dose-dependent
normalization of IPGTT, glucose-stimulated insulin release and
pancreatic insulin content (Figures 4A–4C), our data point to a
Boc5-mediated glycemic control mechanism where restoration of
insulin sensitivity as well as reduction of peripheral demand for
insulin each plays its role. The increased rate of glucose clearance
in response to a fixed (2 IU/kg) amount of insulin (Figure 4D)
provides additional independent evidence for an insulin sensitizing
effect of Boc5 in DIO mice. We know that b-cells adapt to
situations of chronic fuel over-supply and insulin resistance by
increasing their mass [65], which in our hands was elevated 2.4-
fold in untreated obese mice (Figure 5A). Although a non-biased
‘‘systematic uniform random sampling’’ method [66] was not used
in this study to estimate the b-cell area, our findings appear to be
indicative of alterations in several parameters related to b-cell
function after 12 weeks of Boc5 treatment: (i) complete
normalization of b-cell mass; (ii) reduction in islet size; (iii) increase
in small islets (Figure 5); and (iv) suppression of pancreatic
apoptosis. The latter was achieved by a significant decrease of
caspase 3/7 activities in the pancreases of treated mice (Figure S6).
These morphological or biochemical changes are in agreement
with the previous findings with Exendin-4 [67,68], and may
collectively be attributable to the functionality improvement
reflected by enhanced insulin sensitivity, reduced insulin demand
and optimized b-cell efficiency [69].
The subchronic (12 weeks) insulin-sensitizing effect of Boc5
observed here not only reproduces our earlier results generated in
db/db mice [27], but is also consistent with the responses to chronic
GLP-1R agonist treatments in humans [19] and rodents [70,71]
reported elsewhere. Moreover, since adipose tissue has a
substantial influence on systemic glucose homeostasis through
secretion of adipocytokines [49,50], reduced adiposity is likely to
contribute to the preservation of insulin sensitivity as well. Recent
studies have defined adiponectin as an insulin sensitivity mediator
which stimulates tissue fatty acid oxidation and inhibits hepatic
glucose production by activating AMP-activated protein kinase
[72–74]. Our results thus suggest that improvement of insulin
resistance in DIO mice treated with Boc5 may be at least partially
mediated by adiponectin. More importantly, unchanged hyper-
glycemia, hyperinsulinemia, pancreatic insulin content and ITT
response in pair-fed mice clearly indicate an absence of effect by
caloric restriction on insulin sensitivity, thereby implying a possible
dissociation between anorexic and insulin-sensitizing effects of
Boc5 [27]. Obviously, part of the glycemic benefits of Boc5
manifested in obesity is exerted through its potential regulation of
adiposity.
A direct consequence of HFD consumption is increased fat
deposition in both adipocyte stores and non-adipose tissues
including liver and skeletal muscle [75]. Our data confirm that
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enhancement and hepatocyte fat infiltration (Figure 6). In
addition, serum ALT and AST concentrations (Table 2), as
biomarkers of liver integrity, were either elevated or showed such a
tendency in obese mice, suggesting that obesity and steatohepatitis
co-exist in this animal model. Abolishment of liver/muscle fat
accumulation and hepatocyte injury following Boc5 administra-
tion collaborates with the results obtained in ob/ob obese mice and
T2DM patients receiving mid- or long-term Exendin-4 treatment
(60 days and 3 years, respectively) [76,77]. Although insulin
resistance is likely to account for liver and muscle damage [75,78–
80], somewhat surprising is that the apparently less severe tissue fat
infiltration in pair-fed mice occurred without concordant restora-
tion in insulin sensitivity.
It should be noted that 12 weeks’ Boc5 treatment was associated
with remarkable improvements of several dyslipidemia-related
circulating parameters such as elevated TC, TG and LDL/HDL
ratio (Table 2). Although variations of these physiological
measures are influenced by strain/race and diet ingredients [81],
they are believed to be predictive of heart disease and
atherosclerosis in the obese and diabetic populations [5,18,82].
Therefore, intervention of obesity with incretin mimetics may have
the potential to reduce the morbidity of cardiovascular diseases.
Since NEFA released from adipose tissue has been proposed as a
link between obesity and insulin resistance [83], the reduction of
NEFA level resulted from Boc5 therapy (Table 2) may therefore be
one possible mechanism responsible for the restoration of insulin
sensitivity in obese animals. This assumption is consistent with the
low basal lipolytic activity detected in Boc5-treated obese mice,
because circulating NEFA level is a main indicator of basal
lipolysis [84]. There were no significant differences in TC, TG and
NEFA levels between obese and pair-fed animals, indicating that
caloric restriction alone is not sufficient to correct the state of
dyslipidemia in obesity.
In conclusion, this study using a rodent DIO model has
confirmed the glycemic control and weight loss properties of Boc5,
reported previously in db/db mice. Applying an intermittent dosing
protocol, subchronic Boc5 exhibited typical dose-responses in
regulating food intake, adiposity and glucose homeostasis. It is also
efficacious in treating multiple conditions associated with obesity
such as dyslipidemia, adipocytokines dysregulation, adipocyte
malfunction and liver injury. These findings suggest that Boc5 may
produce metabolic benefits via an array of synergistic mechanisms.
Further investigations are required to expand our knowledge on
this class of non-peptidic GLP-1R agonists aiming at pharmaco-
therapies for obesity and related metabolic diseases.
Materials and Methods
Animals and diets
Eight-week old male C57BL/6J mice (18–20 g; Shanghai SLAC
Laboratory Animals Co., Shanghai, China) were housed (two per
cage) at 22.760.8uC in a 12:12 h light:dark cycle. Animals were fed
a HFD (D12492; 60% fat, 20% protein and 20% carbohydrate;
5.24 kcal/g) or a SCD (D12450B; 10% fat, 20% protein and 70%
carbohydrate; 3.85 kcal/g) and watered ad libitum. Both diets were
supplied by Research Diets (New Brunswick, NJ, USA). Animal
experimentation was conducted in accordance with the regulations
approved by the Animal Care and Use Committee, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences.
Experimental design
Experimental animals were maintained on prescribed HFD for
12 weeks and then randomly assigned into 5 treatment groups
(n$6 per group) with matched body weight. They were injected
(i.p.) three times a week, in the mornings of each Monday,
Wednesday and Friday, with 0 (vehicle control), 0.3, 1 or 3 mg
Boc5 (1% DMSO, 20% PEG400 in saline, pH 7.4, 0.5 ml) for 12
weeks. To account for secondary effects that might be due to a
drug-induced reduction in food intake, a pair-fed control group
was presented with the same quantity of food as the Boc5 3 mg
treated group. A further comparator group of mice eating SCD
(n=15) was used to index responses to normal values.
Body weight and food intake were monitored daily. Blood
samples were taken from the tail vein for overnight fasting blood
glucose assessment (using a Freestyle Mini
TM blood glucose
monitoring system; Abbott Diabetes Care Inc., Alameda, CA,
USA) and IPGTT every 3 weeks. Body length was measured at
intervals of 6 weeks for calculation of BMI according to the
formula reported elsewhere [43]. Before and after treatment, ITT
were carried out to estimate insulin sensitivity.
At the end of the study, blood samples were collected and sera
separated subsequently for further analyses. Mice were sacrificed
to dissect and weigh white fat pads (mesenteric, gonadal,
retroperitoneal and inguinal) and BAT according to various
anatomical landmarks [85]. Weights were summed and expressed
as a fraction of total body weight. Fresh gonadal fat pads were used
to assess adipocyte glucose uptake and lipolysis. Pancreas, liver and
skeletal muscle (gastrocnemius) were isolated and frozen by liquid
nitrogen for insulin or lipid content measurement. Inguinal fat
pads, BAT, liver and pancreas were fixed in 10% neutral buffered
formalin for histological or immunohistochemical observation.
The carcasses were stored at 280uC for total body fat evaluation.
Glucose homeostasis
In IPGTT, each animal was fasted overnight, challenged i.p.
with 2 g/kg D-glucose (Sigma-Aldrich, St. Louis, MO, USA)
followed by serial assessment of blood glucose up to 120 min.
Blood samples were collected at 0, 15, 30 and 60 min, respectively,
for subsequent serum insulin analysis using the ELISA kit
(EXRMI-13K) supplied by Linco Research (St. Charles, MO,
USA).
Similar to those developed for clinical use [86], ITT comprised
a 2 IU/kg i.p. challenge with recombinant human insulin
(HumulinH R, Lilly Egypt, Giza, Egypt) in 4-hour fasted mice
followed by glucose sampling at 30 min intervals. The rate of
insulin-mediated fall in blood glucose was quantified to derive an
initial rate of decay (Kitt) as described previously [27].
Immunohistochemical examination of the pancreas
Measurement of islet size and b-cell mass was performed using
methodologies described elsewhere with some modifications
[67,87]. Mice were anesthetized followed by cervical dislocation.
Whole explanted pancreases from six mice per treatment group
(SCD, HFD, 3 mg Boc5 and pair-fed) were rapidly removed,
cleared of fat and lymph nodes, weighed, fixed with 10% formalin
overnight in a flattened position and embedded in paraffin. Ten
consecutive sections (5 mm) of each tissue block, separated by at
least 200 mm, were made and immunostained for insulin or
glucagon. The sections were de-waxed, re-hydrated, and digested
with 0.05% trypsinase at 37uC for 15 min, and blocked by 10%
goat serum (blocking solution) in phosphate buffered saline (PBS)
for 3 h at room temperature (RT). Incubation of samples
overnight at 4uC with polyclonal guinea pig anti-swine insulin
(1:100; DakoCytomation, Carpinteria, CA, USA) or rabbit anti-
human glucagon (1:200; Cell Signaling Technology, Danvers,
MA, USA) antibodies was then conducted in the blocking solution
at RT, followed by twice washing in PBS before reacting with
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Alexa FluorH 568 conjugated goat anti-rabbit IgG antibodies
(Molecular Probes, Eugene, OR, USA) in the blocking solution for
2 h at 37uC. Following two washes with PBS, DAPI (4,6-
diamidino-2-phenylindole, 0.5 mg/ml in PBS) was added onto
the slides that were washed again after 10 min. They were then
mounted with Slowfade Antifade Medium (Invitrogen, Carlsbad,
CA, USA), examined and recorded blindly by two investigators
using an epiflourescence microscope (6100; Olympus, Tokyo,
Japan) with a grey level CCD (charge coupled device) camera
(Olympus).
Histomorphometric measurements were performed with Image-
Pro Plus 6.0 software (Media Cybemetics, Silver Spring, MD,
USA). Six representative sections of each pancreas were chosen for
analysis; each of them was examined for the presence and quantity
of b-cells immunostained positively for insulin, and a minimum of
120 b-cell images per pancreas were analyzed. The cross-sectional
area of b-cells was determined by quantitation of the area
occupied by fluorescently labeled b-cells (green; all fields with b-
cells present, a minimum of 20 images) and the cross-sectional area
of all tissue visualized by DAPI (blue fluorescence). b-cell mass was
estimated as the product of the total cross-sectional b-cell area over
total tissue area and the weight of the pancreas before fixation.
Islet area was traced manually and measured using the above
software to assess islet size distribution. The total numbers of islets
counted for SCD, HFD, 3 mg Boc5 and pair-fed groups were 262,
299, 280 and 263, respectively, and the median islet area for each
group was calculated using the Image-Pro software.
Glucose uptake and lipolytic activities in adipocytes
Isolation of adipocytes. Adipocytes were prepared as
previously described [88–90]. Briefly, gonadal adipose tissue was
dissected out, cut into small fragments and digested with 1 mg/ml
collagenase Type I (Gibco/Invitrogen, Grand Island, NY, USA)
in Krebs’ Ringer phosphate (KRP) buffer (pH 7.4) with 4%
(glucose uptake) bovine serum albumin (BSA; Sigma-Aldrich)
or in KRB buffer with 25 mM Hepes (2-[4-(2-Hydroxyethyl)-
1-piperazinyl]ethanesulfonic acid; Amresco, Solon, OH, USA),
5 mM glucose (Sigma-Aldrich) and 3% (lipolysis) BSA in a
water bath at 37uC for 60 min. The isolated adipocytes were
subsequently filtered through a nylon mesh and washed three
times with KRP buffer containing 0.1% (glucose uptake) BSA or
KPB buffer containing 1% (lipolysis) BSA. They were then
counted, diluted in KRP buffer with 2% (glucose uptake) BSA or
in KRB buffer with 3% (lipolysis) BSA and immediately used for
glucose uptake or lipolysis experiments.
D-[3-
3H]glucose uptake. Glucose uptake (as an index of
lipogenesis) was measured by incorporation of D-[3-
3H]glucose
(PerkinElmer, Boston, MA, USA) into adipocyte lipids as
described elsewhere [91,92]. In brief, the adipocytes were
incubated in KRB buffer with 2% BSA (pH 7.4) containing D-
[3-
3H]glucose (5610
6 dpm/ml), unlabelled glucose (1 mM) and
different concentrations of insulin (0.3–10000 mIU/ml) to give a
final volume of 0.5 ml in a shaking water bath at 37uC. The
incubation was stopped by rapidly chilling on ice and adding 50 ml
H2SO4 (6 M) after 2 h. Each vial was then left overnight with
1.5 ml of toluene-based scintillation liquid including toluene
(Shanghai Chemical Reagents Co, Ltd., Shanghai, China), 2,5-
diphenyloxazole (PPO; Alfa Aesar, Ward Hill, MA, USA) and
1,4 bis (4-methyl-5phenyl-2-oxazoyl) benzene (POPOP; Acros
Organics, Morris Plains, NJ, USA) at RT. The incorporation of
the radiolabeled glucose into the adipocyte lipids was determined
by liquid scintillation counting on the MicroBeta scintillation
counter (PerkinElmer).
Lipolysis. Lipolysis experiments were performed as reported
in the literature [88] and glycerol release was measured as an
index of lipolysis [93]. Briefly, adipocytes, in a final concentration
of approximately 1.5610
6 cells/ml, were incubated for 20 min in
a shaking water bath at 37uC in the presence of 0.1 IU/ml
adenosine deaminase (ADA; Roche Diagnostics GmbH,
Mannheim, Germany). Thereafter, 3, 30 or 300 nM of NA
(Sigma-Aldrich) was added to the adipocytes after a 5-minute
preincubation period. The incubation was stopped 60 min after
the addition of NA. The glycerol release was measured essentially
according to the protocol reported by Laurell et al. [93].
Total body fat determination
Total body fat was measured as described by others [94,95]. In
brief, frozen carcasses were weighed (W1) and autoclaved in
individual sealed beakers with distilled water (20% weight of the
carcasses) for 2.5 h at 120uC. The contents were weighed (W2)
followed by homogenizing into a paste. The latter (10 g) was
lyophilized, weighed (W3) and powdered. Chloroform:methanol
(2:1) solution (20 ml) was used to extract total lipid in 1 g of the
above powder at 40uC overnight. The extraction was filtered and
adjusted to a constant volume (50 ml) with the chloroform:metha-
nol solution. Then 10 ml of the filtrate were dried by rotary
evaporation and the residual fat was weighed (W4). The body fat
percentage was calculated with the formula below:
Body fat (%) ~
W4| 50=10 ðÞ | W3=1 ðÞ | W2=10 ðÞ
W1
|100%
Histology of liver and adipose tissues
Liver and adipose (WAT and BAT) tissues (n=3) from each
group (SCD, HFD, 3 mg Boc5 and pair-fed) were rapidly removed,
fixed in 10% formalin overnight and embedded in paraffin. The
same region of the tissue was used for all animals to minimize
sampling variation that resulted from differences in cell size and
anatomical location. Tissue blocks were sectioned 5 mm thick and
stained with haematoxylin and eosin (H&E). Stained slides were
viewed blindly and independently by two investigators under a
microscope (Olympus) at 6200 magnification and images were
captured by an Olympus C4000 zoom digital camera (Olympus).
The size of the inguinal adipocyte was estimated using Image-Pro
Plus 6.0 software (Media Cybernetics). Representative photomicro-
graphs of the liver and BAT from each group were examined
without statistical analysis. For white adipocyte size determination,
multiple sections (separated by 70–80 mm each) were obtained from
inguinal fat pads. Five representative sections of each mouse were
analyzed for cell size and number using the software. For each
animal,at least10fields(representing approximately 500 adipocytes
collectively) were investigated as described in the literature [96].
Determination of triglyceride contents in the liver and
muscle
Hepatic and muscular TG levels were measured following the
method of Folch et al. [97] with minor modifications. Briefly,
approximately 100 mg of tissue was weighed and homogenized
(17:1,v/wt) inice-cold chloroform:methanol (2:1) solutionfor1 min.
The homogenates were filtered through Whatman No. 1 filter paper
(Whatman Lab Sales Ltd., Maidstone, Kent, UK), which were
subsequently washed (1.5:1, v/wt) by chloroform:methanol solution
twice. The filtrates were mixed with 0.2 volume of 0.9% NaCl
solution and vortexed vigorously for 30 sec. The suspensions were
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chloroform-methanol layer was removed, placed in a new glass
tubeandevaporated todrynessundervacuuminarotaryevaporator
(50–55uC, 200 mBar). The lipid residue was resuspended in 0.5 ml
95% ethanol, and the TG concentration was determined enzymat-
ically using the TG assay kit from Roche Diagnostics.
Blood chemistry
The terminal blood samples were taken from orbital sinus for
determination of fasting serum insulin, leptin and adiponectin
levels using respective ELISA kits (EXRMI-13K, EZML-82K and
EZMADP-60K) supplied by Linco Research.
Serum TG, TC, NEFA, HDL, LDL, ALT and AST were
assayed on a Hitachi 7060 Automatic Analyzer (Tokyo, Japan)
with kits from Roche Diagnostics and Wako Pure Chemical
Industries (for NEFA; Osaka, Japan).
Data analysis and statistical assessment
Dose- and concentration-responses were analyzed using Prism
version 5 software (GraphPad, San Diego, CA, USA) to fit 4-
parameter sigmoid functions. General effects were tested using 1-
way ANOVA. Except where noted otherwise, pair-wise compar-
isons were performed using Dunnett’s test for multiple compar-
isons, and t-test for simple pairs (unpaired t-test, GraphPad). Data
throughout are stated as mean6SEM unless otherwise specified.
Two-tailed significance was tested at a=0.05. Where possible,
experiments were designed with a sample size calculated from
preliminary data to yield a power of B=0.8.
Supporting Information
Figure S1 Fat distribution following 12-week induction with a
high fat diet (HFD). Both white and brown fat mass in normal C57
mice were significantly increased as a percentage of body weight
following 12-week exposure to HFD (n=9). Control animals
received a standard chow diet (SCD; n=8). Values represent
mean6SEM.
DP,0.05 and
DDP,0.01 compared with SCD
group. WAT, white adipose tissue; BAT, brown adipose tissue.
Found at: doi:10.1371/journal.pone.0014205.s001 (0.24 MB TIF)
Figure S2 Normalization of glycemic control by Boc5. Sub-
chronic Boc5 treatment (3 mg, tiw) progressively improved the
area-under-curve values (AUC120) of intraperitoneal glucose
tolerance tests (IPGTTs) carried out every three weeks. Control
animals received a standard chow (SCD) or a high fat (HFD) diet
with vehicle intervention. Values represent mean6SEM (n=6 per
group).
DDP,0.01 compared with SCD group;
**P,0.01 com-
pared with HFD group.
Found at: doi:10.1371/journal.pone.0014205.s002 (0.30 MB TIF)
Figure S3 Morphological examination of pancreases following 12-
week Boc5 therapy. Treatment with Boc5 (3 mg, tiw) for 12 weeks
markedly improved the pancreatic injuries induced by high fat diet
(HFD). Sections (5 mm) of pancreatic tissue from control and Boc5-
treated groups (n=3 per group) were stained with H&E and
representative histological images (6200 original magnification) were
obtained. (A) No histopathological changes were noted in standard
chow diet (SCD) group. (B) In HFD group, larger islets and frequent
microvesicles in islet cells were observed. Enlarged interlobular
interspaces and lipid deposition were also found in some pancreatic
specimens. Inflammatory cell infiltration was not obvious and only a
few lymphocytes were observed in inter- or intra-lobular areas. (C) In
Boc5-treated mice, the alterations induced by HFD were mild. (D)
The histological changes were also seen in pair-fed mouse pancreases
without notable improvement. Scale bars=50 mm.
Found at: doi:10.1371/journal.pone.0014205.s003 (3.24 MB TIF)
Figure S4 Immunohistochemical analysis of pancreatic islets
after 12-week Boc5 administration. Subchronic Boc5 treatment
resulted in a dramatic rise in the number of small islets in the
pancreases of obese mice. Red immunofluorescence staining
indicates glucagon-producing cells and that of green shows
insulin-producing cells. Blue fluorescence is the nuclear staining
and I/G is the merge of the three. Images (6100 original
magnification) were obtained from lean (SCD), obese (HFD), Boc5
(3 mg) and pair-fed treated mouse pancreases, respectively,
following a 12-week therapeutic regimen.
Found at: doi:10.1371/journal.pone.0014205.s004 (8.27 MB TIF)
Figure S5 Sustained weight loss after the cessation of subchronic
Boc5 treatment. Except for standard chow diet (SCD) fed mice, all
other four groups received high fat diet (HFD) without Boc5 or
vehicle intervention. SCD+HFD group was served as DIO control
whereas HFD+Pair-fed group was given an equal amount of food
received by HFD+Boc5 3 mg group. Values represent mean6
SEM (n=8-10 per group).
DP,0.05 and
DDP,0.01 compared
with SCD group;
*P,0.05 and
**P,0.01 compared with HFD
group;
#P,0.05 and
##P,0.01;
$P,0.05 and
$$P,0.01 com-
pared with SCD+HFD group.
Found at: doi:10.1371/journal.pone.0014205.s005 (0.38 MB TIF)
Figure S6 Effect of Boc5 on Caspase 3/7 activity in the
pancreas. Treatment with Boc5 (3 mg, tiw) for 12 weeks
significantly reduced the pancreatic Caspase 3/7 activity of obese
mice. The enzymatic activity was measured using a commercial
Caspase 3/7 Glo assay kit from Promega (Madison, WI, USA).
Relative luminescence unit (RLU) was normalized by the protein
content of the pancreas. Control animals received a standard chow
(SCD) or a high fat (HFD) diet with vehicle intervention. Values
represent mean6SEM (n=8 per group).
DDP,0.01 compared
with SCD group;
**P,0.01 compared with HFD group.
Found at: doi:10.1371/journal.pone.0014205.s006 (0.25 MB TIF)
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